
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)


The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)
Originally reported by NPR. Read the original article